U.S. label record. The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.
A bounded review of two randomized fracture trials in postmenopausal women with osteoporosis, including one placebo comparison and one active comparison with risedronate.↗↗
What the reviewed sources report
Both reviewed trials reported fewer new vertebral fractures with teriparatide than with the comparator. The active-comparator trial did not find a statistically significant difference for its nonvertebral fragility-fracture endpoint.↗↗
What remains unresolved?
How do fracture outcomes, harms, and persistence compare across broader osteoporosis populations and after the reviewed treatment windows?↗↗
The label covers specified high-fracture-risk osteoporosis settings in postmenopausal women, men with primary or hypogonadal osteoporosis, and men or women with glucocorticoid-associated osteoporosis. The male indication refers to increasing bone mass; the postmenopausal account includes fracture-risk reduction. Label: 1 ↗
Which safety limits matter?
The label contraindicates hypersensitivity and addresses osteosarcoma risk, hypercalcemia, cutaneous calcification including calciphylaxis, urinary stones and orthostatic hypotension. It distinguishes the rat osteosarcoma finding from observational human studies in which an increased risk was not observed. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 3d44d13e5c26a6d99016811b324c701e16b0d18d7390d19dd9e3ee5833bb6cb8. Extracted XML SHA-256: a86aaababbba9a8a6ddf6737fbd40d6ecf891c291bb211b5722997e127bf509b.
Fracture outcomes differ from bone-density outcomes
EMA’s initial Forsteo discussion reports fewer new vertebral and non-vertebral fractures in postmenopausal women, but inconclusive results for individual sites such as the hip. Increased bone mineral density is a different endpoint. EMA PDF pp. 21 ↗
More findings, study links and document coverage
Both pivotal trials ended early
The assessment describes early termination of the pivotal trials and median treatment durations of 19 months in women and 11 months in men. These limits matter when interpreting persistence and uncommon adverse effects. EMA PDF pp. 21 ↗
The original male indication was disputed
In this initial assessment, the committee did not accept extrapolating fracture reduction in women to men solely from bone-density results. The original recommendation covered postmenopausal women; later indication extensions require separate review. EMA PDF pp. 21, 22 ↗
Animal findings prompted further surveillance
The review discusses rat osteosarcoma findings and the limits of the then-available human follow-up. It did not establish an observed human cancer risk; this historical concern must be distinguished from later surveillance and current labeling. EMA PDF pp. 20, 21 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
The undated initial scientific discussion names the product. Application identity comes from the separately pinned EMA medicine record, and the date is the documents-feed first-publication date, not an adoption date.
Verified: Forsteo · EMEA/H/C/000425 · EMA first-publication date 2005-10-21. Product identity checked on PDF pp. 1.
The undated PDF does not print the application number. The application is reconciled separately against EMA medicine record EMEA/H/C/000425 ↗, retrieved 2026-09-15. Its first-publication date is not an assessment-adoption date.
Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.
Retrieved 2026-09-19. Read PDF pages: 1, 20, 21, 22 of 22. SHA-256: c0c59f61296f01a3e99817d905b3b96e724f35979e31ab741bab66889db9dec5.
Feed-listed application (not a verified association): EMEA/H/C/000425.
Remaining work
Review subsequent male and glucocorticoid-induced osteoporosis assessments and current labels.
Reconcile long-term human osteosarcoma surveillance and post-treatment fracture follow-up with this historical assessment.
European medicine records · 12 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: teriparatide. EMA record ↗
Application withdrawal: 2020-06-19. EMA metadata last updated 2020-09-28. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
5262 retrieved · 2 included · 0 excluded · 5260 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Teriparatide"[Title/Abstract] OR "parathyroid hormone (1-34)"[Title/Abstract] OR "PTH(1-34)"[Title/Abstract] OR "Teriparatide"[Substance Name]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Linked correction notices require comparison with the selected reports: PMID29198559 for PMID29129436, PMID30527615 for PMID29129436. Their presence does not establish what changed.
Older PTH(1-34) and substance-index searches recover older reports; endogenous physiology and other parathyroid preparations need separate screening.
Showing 25 of 5262 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 29129436 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01709110.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed links an erratum: Department of Error. ↗. Impact on the selected study summary remains unresolved.
Notice XML SHA-256 665a17b3bf95b6880447142e0ff4644a89dcbf3dd0d8b9de4a22c0d9a3f554e0.
PubMed links an erratum: Department of Error. ↗. Impact on the selected study summary remains unresolved.
Notice XML SHA-256 ec5be10c5fc7192f7e1a4a3310a31413c4f12070b431d9ee36600a6a05d0dfa0.
PubMed 11346808 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: teriparatide-PMID11346808-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42734616 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42684545 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42671953 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42656047 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42652552 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42648994 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42635746 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42635731 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42616119 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42614145 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42611824 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42611745 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42605157 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42672530 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 35442604 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42597939 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42597795 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42592840 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42590191 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42587612 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42584962 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42583280 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42579011 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
7 retrieved · 7 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 7 of 7 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA ANDA208569 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
FDA NDA019498 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE ACETATE.
FDA ANDA211097 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
FDA ANDA213641 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
FDA NDA218771 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
FDA NDA021318 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
FDA NDA211939 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TERIPARATIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
12 retrieved · 12 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 12 of 12 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/004932 — include: EMA feed product Kauliv; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/006688 — include: EMA feed product Zandoriah; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/003916 — include: EMA feed product Terrosa; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/004368 — include: EMA feed product Movymia; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/005827 — include: EMA feed product Sondelbay; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/000425 — include: EMA feed product Forsteo; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/005087 — include: EMA feed product Livogiva; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/005793 — include: EMA feed product Teriparatide Sun; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/005687 — include: EMA feed product Teriparatide Ascend; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/005543 — include: EMA feed product Teriparatide Cinnagen; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/005388 — include: EMA feed product Qutavina; reported status: Withdrawn. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/005233 — include: EMA feed product Sondelbay; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
75 retrieved · 67 included · 0 excluded · 8 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 75 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 13908 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - All Authorised presentations
EMA 15954 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - Summary for the public
EMA 20033 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - All Authorised presentations
EMA 27346 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - Summary for the public
EMA 27569 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Scientific Discussion
EMA 27862 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Summary for the public
EMA 32446 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - Public assessment report
EMA 32824 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - All Authorised presentations
EMA 33492 — include: Document linked by EMA product number; content unappraised. Forsteo-H-C-425-II-11 : EPAR - Scientific Discussion - Variation
EMA 35838 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - Public assessment report
EMA 37589 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Procedural steps taken before authorisation
EMA 38968 — include: Document linked by EMA product number; content unappraised. Forsteo-H-C-425-II-13 : EPAR - Scientific Discussion - Variation
EMA 49151 — include: Document linked by EMA product number; content unappraised. Terrosa : EPAR - Risk-management-plan summary
EMA 49156 — include: Document linked by EMA product number; content unappraised. Movymia : EPAR - Risk-management-plan summary
EMA 49730 — include: Document linked by EMA product number; content unappraised. Livogiva : EPAR - All authorised presentations
EMA 49731 — include: Document linked by EMA product number; content unappraised. Livogiva : EPAR - Medicine overview
EMA 49733 — include: Document linked by EMA product number; content unappraised. Livogiva : EPAR - Public assessment report
EMA 49820 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - Medicine overview
EMA 49823 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - All Authorised presentations
EMA 49824 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - Risk-management-plan summary
EMA 49825 — include: Document linked by EMA product number; content unappraised. Qutavina : EPAR - Public assessment report
EMA 50638 — include: Document linked by EMA product number; content unappraised. Forsteo : EPAR - Risk-management-plan summary
EMA 55260 — include: Document linked by EMA product number; content unappraised. Sondelbay : EPAR - Medicine overview
EMA 55263 — include: Document linked by EMA product number; content unappraised. Sondelbay : EPAR - Risk-management-plan summary
EMA 55298 — include: Document linked by EMA product number; content unappraised. Sondelbay : EPAR - Public Assessment Report
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
2 retrieved · 1 included · 1 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EU/3/16/1689 — include: EMA orphan feed identifies teriparatide; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/20/2350 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
214 retrieved · 0 included · 0 excluded · 214 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Teriparatide" OR "parathyroid hormone (1-34)" OR "PTH(1-34)" OR "Kauliv" OR "Zandoriah" OR "Terrosa" OR "Movymia" OR "Sondelbay" OR "Forsteo" OR "Livogiva" OR "Teriparatide Sun" OR "Teriparatide Ascend" OR "Teriparatide Cinnagen" OR "Qutavina"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 214 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT03232476 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01063504 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05993130 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04879420 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00741182 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01896011 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01250145 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01945788 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03623633 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06842758 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00696644 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07028320 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00079924 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00131469 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04241211 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02932501 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02440581 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06061354 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02090244 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00393380 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01801397 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01796301 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05387070 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00347737 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06951776 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Teriparatide?
A bounded review of two randomized fracture trials in postmenopausal women with osteoporosis, including one placebo comparison and one active comparison with risedronate.12
Bottom line from this bounded source set
Both reviewed trials reported fewer new vertebral fractures with teriparatide than with the comparator. The active-comparator trial did not find a statistically significant difference for its nonvertebral fragility-fracture endpoint.12
Reviewed study record
Placebo-controlled fracture trial
Design
A randomized placebo-controlled trial assessed new vertebral and nonvertebral fractures and bone mineral density over a median observation period of 21 months.1
Population
The trial randomized 1,637 postmenopausal women with osteoporosis and prior vertebral fractures.1
Outcomes reported
New vertebral fractures occurred in 14% of the placebo group and 5% and 4% of the two teriparatide groups; nonvertebral fragility fractures occurred in 6% and 3%, respectively.1
Limitations
The population had established postmenopausal osteoporosis with prior vertebral fractures, so the results do not establish effects in people with different baseline risk.1
Reviewed study record
VERO active-comparator fracture trial
Design
A sponsor-funded, double-blind, double-dummy randomized trial compared teriparatide with risedronate over 24 months, with new radiographic vertebral fractures as the primary outcome.2
Population
The trial randomized 1,360 postmenopausal women with severe osteoporosis and qualifying vertebral fractures.2
Outcomes reported
New vertebral fractures were reported in 5.4% of the teriparatide group and 12.0% of the risedronate group. The reported nonvertebral fragility-fracture difference was not statistically significant.2
Limitations
The sponsor-funded results apply to women with severe osteoporosis and existing vertebral-fracture history; the nonvertebral endpoint remained statistically uncertain.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejm200105103441904. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/s0140-6736(17)32137-2. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Teriparatide?
U.S. label record. The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 exact source-declared trial-publication link connects selected NCT and PMID records. Open the exact graph →
PhasesPhase 3 4Phase 4 3Phase 2 2
Status at observationCompleted 9Recruiting 1
A phase value is unavailable here for 64 selected records; this is not counted as “no phase.”
A status value is unavailable here for 63 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
29 of 56 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 27Review 9Research Support, Non-U.S. Gov't 6Comparative Study 4Randomized Controlled Trial 3Case Reports 2Letter 2Multicenter Study 2Clinical Trial 1Comment 1English Abstract 1Observational Study 1
Bibliography fields unavailable here for 27 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
6
FDA Federal Register documents
6
DailyMed SPL versions
8
Canonical profile
Published
Profile structured data
Published
Linked dated records
149
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
PeptideScanner retained ClinicalTrials.gov record NCT02025179 at 2026-07-30T19:13:03.751Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT04750460 at 2026-07-30T19:32:59.860Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was teriparatide.
PubMed lists PMID 18843769 in The Journal of rheumatology as Case Reports, Letter, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PubMed lists PMID 31408164 in The Journal of clinical endocrinology and metabolism as Comment, Letter, with publication-date metadata of 2019-12-01 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 41852535 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 41987916 in JIMD reports as Journal Article, with publication-date metadata of 2026-04-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42058698 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42083710 in Cureus as Journal Article, Review, with publication-date metadata of 2026-04-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42592840 in European journal of endocrinology as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42568899 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42570209 at 2026-08-10T10:49:13.625Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42501079 at 2026-08-10T10:49:10.788Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41904726 at 2026-08-10T10:49:08.825Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41949681 at 2026-08-10T10:49:08.835Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-04-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.↗